ZA200900553B - Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions - Google Patents
Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditionsInfo
- Publication number
- ZA200900553B ZA200900553B ZA200900553A ZA200900553A ZA200900553B ZA 200900553 B ZA200900553 B ZA 200900553B ZA 200900553 A ZA200900553 A ZA 200900553A ZA 200900553 A ZA200900553 A ZA 200900553A ZA 200900553 B ZA200900553 B ZA 200900553B
- Authority
- ZA
- South Africa
- Prior art keywords
- gremlin
- iop
- rnai
- treatment
- related conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83982606P | 2006-08-24 | 2006-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200900553B true ZA200900553B (en) | 2010-04-28 |
Family
ID=39032079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200900553A ZA200900553B (en) | 2006-08-24 | 2007-08-24 | Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions |
Country Status (11)
Country | Link |
---|---|
US (3) | US20080051361A1 (zh) |
EP (1) | EP2059597A2 (zh) |
JP (1) | JP2010501188A (zh) |
KR (1) | KR20090042297A (zh) |
CN (2) | CN101517081A (zh) |
AU (1) | AU2007286545A1 (zh) |
BR (1) | BRPI0715821A2 (zh) |
CA (1) | CA2659464A1 (zh) |
MX (1) | MX2009001896A (zh) |
WO (1) | WO2008024983A2 (zh) |
ZA (1) | ZA200900553B (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
GB0708662D0 (en) * | 2007-05-04 | 2007-06-13 | Galapagos Nv | shRNA sequences |
CN101815536A (zh) * | 2007-10-01 | 2010-08-25 | 爱尔康研究有限公司 | 自补aav介导的干扰rna分子递送以治疗或预防眼病 |
BRPI0802525A2 (pt) | 2008-07-11 | 2010-03-09 | Kiyoshi Hashiba | endoscópio cirúrgico |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US8778904B2 (en) * | 2009-12-09 | 2014-07-15 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the CNS |
CA2794187C (en) | 2010-03-24 | 2020-07-14 | Rxi Pharmaceuticals Corporation | Rna interference in ocular indications |
CA2859127C (en) | 2011-12-15 | 2017-04-25 | Bioneer Corporation | Novel oligonucleotide conjugates and use thereof |
KR101722948B1 (ko) | 2012-01-05 | 2017-04-04 | (주)바이오니아 | 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법 |
US9326941B2 (en) | 2012-01-05 | 2016-05-03 | Bioneer Corporation | High-efficiency nanoparticle-type double-helical oligo-RNA structure and method for preparing same |
EP2805713B1 (en) | 2012-01-18 | 2018-10-10 | Bioneer Corporation | Magnetic nanoparticle-samirna complex and method for preparing same |
WO2013137686A1 (ko) * | 2012-03-15 | 2013-09-19 | 서울대학교 산학협력단 | 그렘린-1에 대한 항체 |
WO2014037686A1 (en) * | 2012-09-05 | 2014-03-13 | Sylentis S.A.U. | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
GB201215857D0 (en) * | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
MX2016000020A (es) | 2013-07-05 | 2016-08-18 | Bioneer Corp | Estructura de nanoparticula del tipo oligonucleotido mejorada que tiene alta eficiencia y metodo para preparar la misma. |
US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
JP2017200928A (ja) * | 2017-05-31 | 2017-11-09 | シレンティス・エセ・ア・ウ | siRNAならびに眼の状態の処置および/または予防のための方法および組成物におけるその使用 |
CN106978509B (zh) * | 2017-06-07 | 2018-10-26 | 中南大学湘雅二医院 | 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0213738A (pt) * | 2001-10-31 | 2006-11-21 | Alcon Inc | proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucoma |
US20040138163A1 (en) * | 2002-05-29 | 2004-07-15 | Mcswiggen James | RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
TW200639252A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
-
2007
- 2007-08-24 KR KR1020097004684A patent/KR20090042297A/ko not_active Application Discontinuation
- 2007-08-24 CN CNA2007800308171A patent/CN101517081A/zh active Pending
- 2007-08-24 AU AU2007286545A patent/AU2007286545A1/en not_active Abandoned
- 2007-08-24 EP EP07841339A patent/EP2059597A2/en not_active Withdrawn
- 2007-08-24 WO PCT/US2007/076776 patent/WO2008024983A2/en active Application Filing
- 2007-08-24 CA CA002659464A patent/CA2659464A1/en not_active Abandoned
- 2007-08-24 MX MX2009001896A patent/MX2009001896A/es active IP Right Grant
- 2007-08-24 BR BRPI0715821-1A patent/BRPI0715821A2/pt not_active IP Right Cessation
- 2007-08-24 JP JP2009525796A patent/JP2010501188A/ja active Pending
- 2007-08-24 ZA ZA200900553A patent/ZA200900553B/xx unknown
- 2007-08-24 CN CN2012102535702A patent/CN102743767A/zh active Pending
- 2007-08-24 US US11/844,869 patent/US20080051361A1/en not_active Abandoned
-
2010
- 2010-06-02 US US12/791,926 patent/US20100305193A1/en not_active Abandoned
-
2011
- 2011-10-26 US US13/281,785 patent/US20120077864A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2659464A1 (en) | 2008-02-28 |
KR20090042297A (ko) | 2009-04-29 |
US20080051361A1 (en) | 2008-02-28 |
AU2007286545A1 (en) | 2008-02-28 |
WO2008024983A2 (en) | 2008-02-28 |
WO2008024983A3 (en) | 2008-10-09 |
CN102743767A (zh) | 2012-10-24 |
US20100305193A1 (en) | 2010-12-02 |
MX2009001896A (es) | 2009-04-17 |
BRPI0715821A2 (pt) | 2013-07-23 |
JP2010501188A (ja) | 2010-01-21 |
CN101517081A (zh) | 2009-08-26 |
US20120077864A1 (en) | 2012-03-29 |
EP2059597A2 (en) | 2009-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200900553B (en) | Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions | |
GB0605337D0 (en) | Treatment of CNS conditions | |
GB2454797B (en) | Treatment of wastewater | |
ZA200900884B (en) | Method of scale inhibition | |
EP2032131A4 (en) | Methods of Treatment | |
EP2174912A4 (en) | PROCESS FOR MACHINING A COPPER ARSEN COMPOUND | |
HK1127294A1 (zh) | 改善多發性骨髓瘤的治療 | |
SG10201404955RA (en) | Rnai inhibition of alpha-enac expression | |
IL195803A0 (en) | Compositions and methods for sirna inhibition of angiogenesis | |
ZA200901364B (en) | Method of treatment of photodermatoses | |
GB0610746D0 (en) | Method of treatment | |
ZA201008192B (en) | A phytosystem for treatment of sewage | |
EP2215035A4 (en) | BISULFIT TREATMENT OF RNA | |
GB0605685D0 (en) | Inhibition of tumour growth | |
EP2072470A4 (en) | METHOD FOR THE REUSE OF WASTE WATER | |
EP1988060A4 (en) | METHOD FOR TREATING WASTEWATER | |
EP1986656A4 (en) | WITHACNISTINE COMPOUNDS FOR THE TREATMENT OF CANCER | |
EP2367544A4 (en) | METHOD FOR TREATING AGGRESSION | |
GB0701722D0 (en) | Inhibition of gene expression | |
EP2188219A4 (en) | METHOD FOR WATER TREATMENT COMPRISING NON-POLAR COMPOUNDS | |
GB0723100D0 (en) | Treatment of HFnEF | |
EP1966368A4 (en) | INHIBITION OF RNA-I-INDUCED IGFLR FOR THE TREATMENT OF OCULAR ANGIOGENESIS | |
EP2344424A4 (en) | ELIMINATION OF ARSENIC FROM WATER | |
EP2094385A4 (en) | METHOD OF WASTE WATER TREATMENT | |
GB0611417D0 (en) | Treatment of cndaria intoxication |